Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL745728

CN1C2CCC1CC(Oc1ccc(-c3ccc4c(ccn4C)c3)nn1)C2.O=C(O)C(F)(F)F

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD11B1 P28845 1/20 0.37
HTR3A P46098 4/20 0.36
HTR3E A5X5Y0 2/20 0.36
HTR3B O95264 2/20 0.36
HTR3D Q70Z44 2/20 0.36
HTR3C Q8WXA8 2/20 0.36
ACACB O00763 1/20 0.36
ACACA Q13085 1/20 0.36
CHRNA7 P36544 1/20 0.35
TRPV3 Q8NET8 1/20 0.35
KDM1A O60341 1/20 0.34
OPRK1 P41145 1/20 0.34
HTT P42858 1/20 0.34
PRKAG1 P54619 1/20 0.34
PRKAA1 Q13131 1/20 0.34
PRKAB1 Q9Y478 1/20 0.34
SLC6A2 P23975 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL745674 0.91 CHRNA7 (0.40) NPC1RAB9ASMN1; SMN2HSD11B1CHRNA7
Trifluoroacetic Acid SCHEMBL744964 0.85 CHRNA7 (0.52) SMN1; SMN2HTR3AHTR3EHTR3BHTR3D
Trifluoroacetic Acid SCHEMBL764686 0.84 CHRNA7 (0.44) HTR3AHTR3EHTR3BHTR3DHTR3C
Trifluoroacetic Acid SCHEMBL990616 0.83 CHRNA7 (0.45) HTR3AHTR3EHTR3BHTR3DHTR3C
Trifluoroacetic Acid SCHEMBL990815 0.83 CHRNA7 (0.46) HTR3AHTR3EHTR3BHTR3DHTR3C
Trifluoroacetic Acid SCHEMBL990814 0.83 CHRNA7 (0.46) HTR3AHTR3EHTR3BHTR3DHTR3C
Trifluoroacetic Acid SCHEMBL745211 0.83 CHRNA7 (0.45) HTR3AHTR3EHTR3BHTR3DHTR3C
Trifluoroacetic Acid SCHEMBL747090 0.82 CHRNA7 (0.51) SMN1; SMN2HTR3AHTR3EHTR3BHTR3D
Trifluoroacetic Acid SCHEMBL745269 0.81 CHRNA7 (0.50) SMN1; SMN2ACACBACACACHRNA7HTT
Trifluoroacetic Acid SCHEMBL1542595 0.81 CHRNA7 (0.56) NPC1RAB9ASMN1; SMN2HSD11B1HTR3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2431368-A1 CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives Abbott Laboratories (US) 2012-03-21 EP disclosed
EP-2018380-B1 Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LAB (US) 2011-10-19 EP disclosed
US-7872017-B2 Fused bicycloheterocycle substituted azabicyclic alkane derivatives ABBOTT LABORATORIES (US) 2011-01-18 US disclosed
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives ABBOTT LABORATORIES (US) 2010-12-02 US disclosed
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES ABBVIE INC. 2008-02-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045539-A1 FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES MALT1, BMP2, ALKBH2 NPC1 50/4885RAB9A 2356/4885SMN1; SMN2 1373/4885
US-20100305089-A1 Fused Bicycloheterocycle Substituted Azabicyclic Alkane Derivatives MALT1, BMP2, ALKBH2 NPC1 50/4885RAB9A 2356/4885SMN1; SMN2 1373/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.